
Marjatta Leirisalo-Repo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3146609/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sulfasalazine in the treatment of spondylarthropathy. Arthritis and Rheumatism, 1995, 38, 618-627.	6.7	378
2	Doubleâ€blind, placeboâ€controlled study of threeâ€month treatment with lymecycline in reactive arthritis, with special reference to <i>Chlamydia</i> arthritis. Arthritis and Rheumatism, 1991, 34, 6-14.	6.7	273
3	High Frequency of Silent Inflammatory Bowel Disease in Spondylarthropathy. Arthritis and Rheumatism, 1994, 37, 23-31.	6.7	196
4	Ten-year followup study of patients withyersinia arthritis. Arthritis and Rheumatism, 1988, 31, 533-537.	6.7	111
5	Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 52-58.	0.9	111
6	Long term prognosis of reactive salmonella arthritis. Annals of the Rheumatic Diseases, 1997, 56, 516-520.	0.9	96
7	Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis and Rheumatism, 2000, 43, 2397-2401.	6.7	93
8	Reactive arthritis. Scandinavian Journal of Rheumatology, 2005, 34, 251-259.	1.1	87
9	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nature Communications, 2017, 8, 15869.	12.8	83
10	Progression of cervical spine changes in patients with early rheumatoid arthritis. Journal of Rheumatology, 1997, 24, 1280-4.	2.0	83
11	Salmonella-triggered reactive arthritis: Use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis and Rheumatism, 1999, 42, 84-89.	6.7	77
12	Infliximab for 6â€months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo) Tj ETQq0 0 () rg bT 9Ove	erlo zla 10 Tf 50
13	Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 815-821.	6.7	74
14	Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth―strategy. Arthritis and Rheumatism, 1996, 39, 996-1005.	6.7	67
15	Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatology International, 2001, 20, 192-196.	3.0	62
16	Clonal hematopoiesis in patients with rheumatoid arthritis. Blood Cancer Journal, 2018, 8, 69.	6.2	62
17	Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population. BMJ Open, 2017, 7, e011916.	1.9	61
18	IL10.G microsatellites mark promoter haplotypes associated with protection against the development	6.7	59

	againet are accoplinent
18 19 19 19 19 19 19 19 19 19 19 19 19 19	
¹⁰ of reactive arthritic in Linnich patients. Arthritic and Dhoumatism 2001 44	1000 1017
of reactive arthritis in Finnish patients. Arthritis and Rheumatism, 2001, 44,	

#	Article	IF	CITATIONS
19	Rheumatoid Atlantoaxial Subluxation Can Be Prevented by Intensive Use of Traditional Disease Modifying Antirheumatic Drugs. Journal of Rheumatology, 2009, 36, 273-278.	2.0	50
20	Somatic <i>STAT3</i> mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. Haematologica, 2018, 103, 304-312.	3.5	50
21	Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: An early marker of progressive erosive disease. Arthritis and Rheumatism, 2000, 43, 1371-1377.	6.7	49
22	Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clinical and Experimental Rheumatology, 2006, 24, 295-301.	0.8	48
23	The Present Knowledge of the Inflammatory Process and the Inflammatory Mediators. Basic and Clinical Pharmacology and Toxicology, 1994, 75, 1-3.	0.0	44
24	Microbial factors in spondyloarthropathies: insights from population studies. Current Opinion in Rheumatology, 2003, 15, 408-412.	4.3	40
25	Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Annals of the Rheumatic Diseases, 2014, 73, 1954-1961.	0.9	40
26	Early arthritis and infection. Current Opinion in Rheumatology, 2005, 17, 433-439.	4.3	39
27	Impact of rheumatic diseases on oral health and quality of life. Oral Diseases, 2015, 21, 342-348.	3.0	35
28	Are antibiotics of any use in reactive arthritis?. Apmis, 1993, 101, 575-581.	2.0	32
29	Agalactosyl IgC is elevated in patients with active spondyloarthropathy. Rheumatology International, 1999, 18, 171-176.	3.0	30
30	Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial. PLoS ONE, 2017, 12, e0183294.	2.5	30
31	The effect of cryotherapy on total antioxidative capacity in patients with active seropositive rheumatoid arthritis. Rheumatology International, 2017, 37, 1481-1487.	3.0	29
32	Inflammatory biomarkers in saliva and serum of patients with rheumatoid arthritis with respect to periodontal status. Annals of Medicine, 2018, 50, 333-344.	3.8	26
33	Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. Clinical Science, 1999, 96, 287-295.	4.3	24
34	Platelet autoantibodies detected by immunoblotting in systemic lupus erythematosus: Association with the lupus anticoagulant, and with history of thrombosis and thrombocytopenia. European Journal of Haematology, 1990, 44, 234-239.	2.2	24
35	Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0137385.	2.5	24
36	Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response. Frontiers in Immunology, 2021, 12, 738481.	4.8	23

#	Article	IF	CITATIONS
37	Time Course of β2-Integrin CD11b/CD18 (Mac-1, αMβ2) Upregulation on Neutrophils and Monocytes after Coronary Artery Bypass Grafting:CD11b upregulation after CABG surgery. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1996, 30, 141-148.	0.2	21
38	A Review of Serological Tests to Assist Diagnosis of Reactive Arthritis: Critical Appraisal on Methodologies. Frontiers in Immunology, 2013, 4, 418.	4.8	20
39	Therapeutic Aspects of Spondyloarthropathies - A Review. Scandinavian Journal of Rheumatology, 1998, 27, 323-328.	1.1	18
40	Antiâ€rheumatic medication and salivary MMPâ€8, a biomarker for periodontal disease. Oral Diseases, 2018, 24, 1562-1571.	3.0	17
41	The Significance of Serum Anti-Borrelia Antibodies in the Diagnostic Work-Up of Uveitis. European Journal of Ophthalmology, 1997, 7, 251-255.	1.3	16
42	Yersinia enterocolitica biotype 1A: a possible new trigger of reactive arthritis. Rheumatology International, 2017, 37, 1863-1869.	3.0	16
43	STAT6 and STAT1 Pathway Activation in Circulating Lymphocytes and Monocytes as Predictor of Treatment Response in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0167975.	2.5	15
44	Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 75.	3.5	13
45	Cardiac magnetic resonance imaging reveals frequent myocardial involvement and dysfunction in active rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 416-23.	0.8	13
46	Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study. Journal of Rheumatology, 2020, 47, 1160-1164.	2.0	12
47	Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic <i>Escherichia coli</i> (DEC). Annals of the Rheumatic Diseases, 2020, 79, 605-611.	0.9	12
48	What is the best treatment strategy for early RA?. Best Practice and Research in Clinical Rheumatology, 2013, 27, 523-536.	3.3	11
49	Activity of rheumatoid arthritis correlates with oral inflammatory burden. Rheumatology International, 2018, 38, 1661-1669.	3.0	11
50	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Frontiers in Immunology, 2020, 11, 578848.	4.8	11
51	Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis Annals of the Rheumatic Diseases, 1990, 49, 615-619.	0.9	10
52	Different DRB1*04 alleles predominate in the Finnish random population and in HLAâ€B27â€positive subpopulations. Tissue Antigens, 1994, 44, 329-331.	1.0	9
53	Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach. Rheumatology International, 2017, 37, 825-830.	3.0	9
54	Enhanced Inflammatory Reactivity in the Pathogenesis of Spondyloarthropathies. Autoimmunity, 1990, 7, 245-254.	2.6	8

MARJATTA LEIRISALO-REPO

#	Article	IF	CITATIONS
55	High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 1689-1694.	2.2	8
56	Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2021, 50, 262-270.	1.1	8
57	Impaired Akt Phosphorylation in Monocytes of Patients with Rheumatoid Arthritis. Scandinavian Journal of Immunology, 2017, 85, 155-161.	2.7	7
58	One-Year Follow-up Study Detects Myocardial Changes with Cardiovascular Magnetic Resonance Tagging in Active Rheumatoid Arthritis. Academic Radiology, 2018, 25, 476-485.	2.5	7
59	Pretreatment resistin levels are associated with erosive disease in early rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs and infliximab. Scandinavian Journal of Rheumatology, 2022, 51, 180-185.	1.1	7
60	Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the Randomized Clinical NEO-RACo Trial. Journal of Rheumatology, 2014, 41, 2379-2385.	2.0	6
61	ANTIâ€DNA ANTIBODIES: THE CHOICE OF ASSAYS FOR ROUTINE DIAGNOSTIC WORK. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section C, Immunology, 1985, 93C, 13-18.	0.2	5
62	Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission. Rheumatology Advances in Practice, 2021, 5, rkab030.	0.7	5
63	Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial. Clinical and Experimental Rheumatology, 2016, 34, 1038-1044.	0.8	5
64	Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. Clinical and Experimental Rheumatology, 2016, 34, 1065-1071.	0.8	5
65	Serum Epstein-Barr virus DNA, detected by droplet digital PCR, correlates with disease activity in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 778-784.	0.8	5
66	FRI0185â€In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50 mg or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind study. Annals of the Rheumatic Diseases, 2013, 72, A434.3-A435.	0.9	4
67	Early Targeted Combination Treatment With Conventional Synthetic Diseaseâ€Modifying Antirheumatic Drugs and Longâ€Term Outcomes in Rheumatoid Arthritis: Tenâ€Year Followâ€Up Results of a Randomized Clinical Trial. Arthritis Care and Research, 2019, 71, 1450-1458.	3.4	4
68	THU0178â€Comprehensive Disease Control with Golimumab in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A223.3-A224.	0.9	3
69	Renal diseases in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2016, 45, 432-433.	1.1	3
70	Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis. Rheumatology International, 2022, 42, 1015-1025.	3.0	3
71	Gut and spondyloarthropathies. Rheumatic Disease Clinics of North America, 1992, 18, 23-35.	1.9	3
72	Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. Clinical and Experimental Rheumatology, 2016, 34, 184-90.	0.8	3

#	Article	IF	CITATIONS
73	THU0119â€Impact of Neglecting Intra-Articular Glucocorticoid-Injections in Remission Targeted Treatment of Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 237.2-237.	0.9	2
74	AB0373â€Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 928-928.	0.9	1
75	Induction of remission in female rheumatoid arthritis patients is associated with stabilization of myocardial abnormalities: a prospective cardiac magnetic resonance follow-up study. Scandinavian Journal of Rheumatology, 2021, 50, 104-112.	1.1	1
76	FRI0092â€Disease activity at three months is an excellent predictor of long-term treatment failure in actively treated rheumatoid arthritis patients, 5-year results of the neo-raco trial. Annals of the Rheumatic Diseases, 2013, 72, A400.2-A401.	0.9	0
77	FRIO254â€Predictive Value of Pretreatment Resistin Levels for Erosive Disease in Early RA Treated with DMARDS and Infliximab. Annals of the Rheumatic Diseases, 2014, 73, 475.2-475.	0.9	0
78	AB0362â€Depressive Symptoms and the Risk of Work Disability in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1014.2-1014.	0.9	0
79	A6.02â€Somatic mutations in clonally expanded CD8 ⁺ T cells in patients with newly diagnosed rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A47.2-A48.	0.9	0
80	OP0024â€Drug trough levels and antidrug antibodies in nonselected ankylosing spondylitis patients using self-injected antitnf drugs. , 2017, , .		0
81	AB0250â€TOFACITINIB SUPPRESSES SEVERAL JAK-STAT PATHWAYS IN RHEUMATOID ARTHRITIS AND BASELINE SIGNALING PROFILE ASSOCIATES WITH TREATMENT RESPONSE. Annals of the Rheumatic Diseases, 2021, 80, 1150.2-1151.	0.9	0
82	Myocardial changes detected with modern cardiac magnetic resonance techniques in patients with early rheumatoid arthritis. European Heart Journal Cardiovascular Imaging, 2021, 22, .	1.2	0
83	THU0200â€Subcutaneous tocilizumab in patients with rheumatoid arthritis; a high number of patients achieve doppler remission after 24 weeks. , 2018, , .		0